Prostate cancer news
Targeted treatment up front improves survival for advanced prostate cancer, and we predict a change in thinking for precision cancer medicine.
Scientists have developed a blood test that could help doctors select the best treatment for men with aggressive prostate cancer.
We take a look at results from the STAMPEDE clinical trial, which is researching how to improve treatment for men with prostate cancer.
Offering abiraterone (Zytiga) up-front with standard hormone treatment extends survival in men whose prostate cancer has spread.
Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent.